Our findings identify miR‐106a and LITAF as novel modulators of radioresistance through ATM upregulation and suggest that miR‐106a may be a promising biomarker for high‐grade disease and radioresistant prostate cancer. This evidence concerns the gene LITAF and prostate cancer.